AI assistant
INCYTE CORP — Director's Dealing 2024
Jul 17, 2024
30371_dirs_2024-07-17_554789dc-0f7d-4176-b22e-e5e6960d833a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INCYTE CORP (INCY)
CIK: 0000879169
Period of Report: 2024-07-15
Reporting Person: Trotta Matteo (EVP, GM, Dermatology US)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-07-15 | Common Stock | A | 2646 | — | Acquired | 10474 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-07-15 | Employee Stock Option (right to buy) | $64.25 | A | 5921 | Acquired | 2034-07-14 | Common Stock (5921) | Direct |
Footnotes
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 15, 2024 grant, this includes an aggregate of 10,474 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.